Recombinant Cyclin Dependent Kinase Inhibitor 2A (CDKN2A) Homo sapiens (Human) Recombinant protein

P16; ARF; CDK4I; CMM2; INK4; INK4a; MLM; MTS1; TP16; P14; P14ARF; P16INK4a; P19; Melanoma P16; Cyclin-dependent kinase 4 inhibitor A; Multiple tumor suppressor 1

Add to Cart Distributors
Overview
Properties
  • Source Prokaryotic expression, Host E.coli
  • Endotoxin Level<1.0EU per 1µg (determined by the LAL method)
  • Subcellular LocationCytoplasm, Chromosome
  • Molecular Mass 19.7kDa, Accurate 20kDa(Analysis of differences refer to the manual)
  • Residues & TagsSer8~Asp156 with N-terminal His Tag
  • Buffer FormulationPBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
  • Traits Freeze-dried powder, Purity > 95%
  • Isoelectric Point6.4
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • Recombinant Cyclin Dependent Kinase Inhibitor 2A (CDKN2A) Packages (Simulation)
  • Recombinant Cyclin Dependent Kinase Inhibitor 2A (CDKN2A) Packages (Simulation)
  • Recombinant Cyclin Dependent Kinase Inhibitor 2A (CDKN2A) Figure . Gene Sequencing (extract)
  • RPA794Hu01.jpg Figure. SDS-PAGE
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Sequence

Usage

Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

Storage

Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.

Stability

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

Citations

  • Comparison of Selected Protein Levels in Tumour and Surgical Margin in a Group of Patients with Oral Cavity Cancerpubmed:28421310
  • Development of core-shell nanocarrier system for augmenting piperine cytotoxic activity against human brain cancer cell linePubmed:29597041
  • Senescence-associated miR-34a and miR-126 in middle-aged Indians with type 2 diabetesPubmed: 31732824
  • Tumor suppressor genes are differentially regulated with dietary folate modulations in a rat model of hepatocellular carcinomaPubmed: 32974833

Recommend products